Matches in SemOpenAlex for { <https://semopenalex.org/work/W2930739574> ?p ?o ?g. }
- W2930739574 endingPage "30" @default.
- W2930739574 startingPage "27" @default.
- W2930739574 abstract "Two new Pt(II) complexes with sorafenib (SRFN) and regorafenib (RGFN), having the general formulae [Pt(SRFN)(DMSO)Cl2] (SRFN-Pt) and [Pt(RGFN)(DMSO)Cl2] (RGFN-Pt), were prepared and characterized by ESI-MS, IR, UV–Vis spectroscopy, elemental analyses, and 1H and 13C NMR, respectively. The anticancer activities of SRFN-Pt and RGFN-Pt were evaluated by MTT assay with NCI-H460 (human non-small cell lung cancer NCI-H460 cell line), SK-OV-3 (ovarian cancer cell line), SK-OV-3/DDP (cisplatin-resistant SK-OV-3 cell line), T-24 (human bladder cancer cell line), HeLa (cervical cancer cell line), A549/DDP (cisplatin-resistant A549/DDP non-small cell lung cancer cell line) cancer cells and in the normal HL-7702 cells. The results suggested that SRFN-Pt and RGFN-Pt were more effective against the A549/DDP tumor cells (IC50 = 1.18 ± 0.15 μM and 0.13 ± 0.03 μM) than SRFN (45.03 ± 0.79 μM), RGFN (40.11 ± 2.15 μM), and cisplatin (97.63 ± 1.06 μM), respectively, and RGFN-Pt was more effective than SRFN-Pt. In addition, SRFN-Pt and RGFN-Pt induced G2/M and S phase arrest. Cytotoxic mechanism studies revealed that SRFN-Pt and RGFN-Pt triggered mitochondria-mediated apoptotic cell death at low concentration. RGFN-Pt exhibited obvious priority on the in vitro antitumor activity than SRFN-Pt, which should be undoubtedly correlated with the key roles of the fluoro substituted groups in the RGFN ligand of RGFN-Pt. The in vitro anti-tumor activity studies suggested that RGFN-Pt pointed to a new direction in developing Pt(II) drugs as anti-cancer agent." @default.
- W2930739574 created "2019-04-11" @default.
- W2930739574 creator A5019054262 @default.
- W2930739574 creator A5020900553 @default.
- W2930739574 creator A5048352507 @default.
- W2930739574 creator A5052931863 @default.
- W2930739574 creator A5057994349 @default.
- W2930739574 creator A5059996188 @default.
- W2930739574 creator A5071933035 @default.
- W2930739574 creator A5089456789 @default.
- W2930739574 date "2019-06-01" @default.
- W2930739574 modified "2023-10-16" @default.
- W2930739574 title "Two novel platinum(II) complexes with sorafenib and regorafenib: Synthesis, structural characterization, and evaluation of in vitro antitumor activity" @default.
- W2930739574 cites W1152685973 @default.
- W2930739574 cites W1890488616 @default.
- W2930739574 cites W1969436685 @default.
- W2930739574 cites W1971084892 @default.
- W2930739574 cites W1974693247 @default.
- W2930739574 cites W1982265409 @default.
- W2930739574 cites W1989171624 @default.
- W2930739574 cites W1990584804 @default.
- W2930739574 cites W1992438153 @default.
- W2930739574 cites W1996868772 @default.
- W2930739574 cites W2001857392 @default.
- W2930739574 cites W2006031607 @default.
- W2930739574 cites W2012108057 @default.
- W2930739574 cites W2015621995 @default.
- W2930739574 cites W2016730049 @default.
- W2930739574 cites W2017588171 @default.
- W2930739574 cites W2029434164 @default.
- W2930739574 cites W2033271093 @default.
- W2930739574 cites W2033336453 @default.
- W2930739574 cites W2046881199 @default.
- W2930739574 cites W2047027724 @default.
- W2930739574 cites W2047182883 @default.
- W2930739574 cites W2052508495 @default.
- W2930739574 cites W2060886247 @default.
- W2930739574 cites W2061410259 @default.
- W2930739574 cites W2067586362 @default.
- W2930739574 cites W2078198776 @default.
- W2930739574 cites W2098578468 @default.
- W2930739574 cites W2115571693 @default.
- W2930739574 cites W2122141445 @default.
- W2930739574 cites W2138236417 @default.
- W2930739574 cites W2151941489 @default.
- W2930739574 cites W2163290388 @default.
- W2930739574 cites W2168076926 @default.
- W2930739574 cites W2169996328 @default.
- W2930739574 cites W2199102655 @default.
- W2930739574 cites W2203908584 @default.
- W2930739574 cites W2313816934 @default.
- W2930739574 cites W2317656594 @default.
- W2930739574 cites W2323618732 @default.
- W2930739574 cites W2324498092 @default.
- W2930739574 cites W2329555214 @default.
- W2930739574 cites W2407646435 @default.
- W2930739574 cites W2419243010 @default.
- W2930739574 cites W2463478655 @default.
- W2930739574 cites W2464056483 @default.
- W2930739574 cites W2514780597 @default.
- W2930739574 cites W2525035163 @default.
- W2930739574 cites W2559988443 @default.
- W2930739574 cites W2562134299 @default.
- W2930739574 cites W2564162332 @default.
- W2930739574 cites W2594884523 @default.
- W2930739574 cites W2602449254 @default.
- W2930739574 cites W2605688705 @default.
- W2930739574 cites W2605856867 @default.
- W2930739574 cites W2608372947 @default.
- W2930739574 cites W2707233952 @default.
- W2930739574 cites W2765362780 @default.
- W2930739574 cites W2765974508 @default.
- W2930739574 cites W2767643000 @default.
- W2930739574 cites W2772735971 @default.
- W2930739574 cites W2776992478 @default.
- W2930739574 cites W2781801026 @default.
- W2930739574 cites W2790552830 @default.
- W2930739574 cites W2884844055 @default.
- W2930739574 cites W2891064748 @default.
- W2930739574 cites W2893692955 @default.
- W2930739574 cites W2897458056 @default.
- W2930739574 cites W4248242318 @default.
- W2930739574 doi "https://doi.org/10.1016/j.inoche.2019.03.031" @default.
- W2930739574 hasPublicationYear "2019" @default.
- W2930739574 type Work @default.
- W2930739574 sameAs 2930739574 @default.
- W2930739574 citedByCount "8" @default.
- W2930739574 countsByYear W29307395742019 @default.
- W2930739574 countsByYear W29307395742020 @default.
- W2930739574 countsByYear W29307395742021 @default.
- W2930739574 countsByYear W29307395742022 @default.
- W2930739574 countsByYear W29307395742023 @default.
- W2930739574 crossrefType "journal-article" @default.
- W2930739574 hasAuthorship W2930739574A5019054262 @default.
- W2930739574 hasAuthorship W2930739574A5020900553 @default.
- W2930739574 hasAuthorship W2930739574A5048352507 @default.
- W2930739574 hasAuthorship W2930739574A5052931863 @default.
- W2930739574 hasAuthorship W2930739574A5057994349 @default.